HEOR - Director, Methods

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life‑changing medicines, strengthen how health is understood and managed, and support the communities we serve.

This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life‑changing medicines, strengthen how health is understood and managed, and support the communities we serve.

This is hard, urgent, selfless work—but it's work worth doing. If you're driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.

This role provides methodological leadership across the full span of HEOR evidence generation, including comparative effectiveness and pharmacoepidemiologic methods, systematic literature review and meta‑analytic techniques (network meta‑analysis and indirect treatment comparison), health technology assessment methodology, and cost‑effectiveness and economic modeling. The successful candidate will have deep expertise in causal inference methods for observational data (target trial emulation, active‑comparator new‐user design, marginal structural models), quantitative synthesis methods for building comparative evidence in the absence of head‑to‑head trials, and the construction and critique of decision‑analytic models (Markov, discrete event simulation, budget impact) used to support payer and HTA submissions.

This person functions as the internal scientific authority ensuring that evidence generation, from observational study design through economic modeling, meets the rigor required for regulatory engagement, HTA body review, and payer value communication, while partnering closely with biostatistics, epidemiology, global market access, and external academic and consulting collaborators.

Candidates should bring a strong publication record spanning comparative effectiveness, meta‑analytic, or health economic methods, direct experience building or critiquing cost‑effectiveness models and HTA dossiers (NICE, ICER, or comparable bodies), and the judgment to identify where methodological choices in any of these domains create downstream regulatory, payer, or scientific risk.

The demand for high‑quality health economic and outcomes research (HEOR) and real‑world evidence (RWE) to support drug development, health technology assessment/access decisions, product differentiation, and clinical decision making continues to grow. The purpose of the Lilly Health Economic and Outcome Research team is to accelerate equitable patient access and transform healthcare delivery through the execution and communication of bold, high impact science.

HEOR provides strategic insight/leadership into the health outcomes (HO) evidence needs (e.g., health economics, patient reported outcomes, real world evidence, access and reimbursement) for Lilly’s portfolio. As an HEOR technical lead within the cardiometabolic health (CMH) business unit, this individual partners to develop the real‑world evidence,…